Target intelligence / Profile preview

RCAN2 divergent transcript (RCAN2-DT)

Target
RCAN2-DT
Molecular classification
Long noncoding RNA, noncoding RNA, divergent transcript
01

Overview

RCAN2-DT (RCAN2 divergent transcript) is annotated as a noncoding RNA gene (RNA gene), produced from the divergent transcription at the RCAN2 locus. Divergent transcripts are typically noncoding RNA species transcribed in the orientation opposite to a protein-coding gene's promoter, frequently with unclear function. There are no data to indicate that RCAN2-DT encodes a protein or is a validated target for drugs, nor is there evidence linking it directly to disease processes or biomarker status. Most research on the RCAN family pertains to the protein-coding gene RCAN2, which is involved in calcineurin regulation and has roles in cellular signaling, cilia function, and potentially disease; however, "RCAN2-DT" specifically refers to the noncoding transcript, not the protein[1][7][8]. Summary: RCAN2-DT is not a therapeutic or canonical protein target; it is a noncoding RNA gene with no established biomedical role. Information about the protein RCAN2 should not be conflated with RCAN2-DT.

Other names
RCAN2-DTRCAN2 divergent transcript
02

Biological functions

Unknown (no validated biological function as a protein or enzyme; noncoding RNA function not well characterized)
03

Disease associations

Unknown (no established role in disease; studies focus on the RCAN2 protein, not the divergent transcript)

Beyond the preview

Go deeper on RCAN2 divergent transcript (RCAN2-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCAN2 divergent transcript (RCAN2-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call